{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:50:29Z","timestamp":1776804629632,"version":"3.51.2"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T00:00:00Z","timestamp":1506470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.neo.2017.10.008","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T09:15:59Z","timestamp":1511342159000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"20","author":[{"given":"Cathy C","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Jackson-Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui Stephen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conglin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanni","family":"Huser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puja","family":"Sapra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2017.10.008_bb0005","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","article-title":"Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells","volume":"97","author":"van Der Velden","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.neo.2017.10.008_bb0010","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2141.2008.07153.x","article-title":"Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving gemtuzumab in the course of the disease","volume":"143","author":"Chevallier","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neo.2017.10.008_bb0015","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neo.2017.10.008_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ajh.23893","article-title":"Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia","volume":"90","author":"Maurillo","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neo.2017.10.008_bb0025","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","article-title":"High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival","volume":"11","author":"van Rhenen","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2017.10.008_bb0030","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/leu.2012.217","article-title":"The proportion of CD34 (+) CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia","volume":"27","author":"Roshal","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2017.10.008_bb0035","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nbt1350","article-title":"Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region","volume":"25","author":"Ishikawa","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neo.2017.10.008_bb0040","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.neo.2017.10.008_bb0045","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood-2013-07-513044","article-title":"Crenolanib is active against models of drug-resistant FLT3-ITD\u2013positive acute myeloid leukemia","volume":"122","author":"Zimmerman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.neo.2017.10.008_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1158\/1078-0432.CCR-08-0897","article-title":"Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models","volume":"15","author":"Zhang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2017.10.008_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120925","article-title":"An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence Imaging","volume":"10","author":"Vick","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2017.10.008_bb0060","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.neo.2017.10.008_bb0065","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s12185-013-1334-8","article-title":"FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance","volume":"97","author":"Grunwald","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.neo.2017.10.008_bb0070","first-page":"3619","article-title":"Evolution of karyotypes in acute nonlymphocytic leukemia","volume":"39","author":"Testa","year":"1979","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2017.10.008_bb0075","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"N. Cancer Genome Atlas Research","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2017.10.008_bb0080","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2017.10.008_bb0085","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2017.10.008_bb0090","series-title":"Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human phase 1 studies","author":"Deslandes","year":"2014"},{"key":"10.1016\/j.neo.2017.10.008_bb0095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1586\/17512433.2013.827405","article-title":"Preclinical and clinical pharmacokinetic\/pharmacodynamic considerations for antibody-drug conjugates","volume":"6","author":"Sapra","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.neo.2017.10.008_bb0100","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2741\/4181","article-title":"Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin","volume":"18","author":"Cowan","year":"2013","journal-title":"Front Biosci(Landmark edition)"},{"key":"10.1016\/j.neo.2017.10.008_bb0105","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","article-title":"FLT3: ITDoes matter in leukemia","volume":"17","author":"Levis","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2017.10.008_bb0110","first-page":"7","article-title":"Flt3 inhibitors: recent advances and problems for clinical application","volume":"77","author":"Kiyoi","year":"2015","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.neo.2017.10.008_bb0115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4252\/wjsc.v6.i4.473","article-title":"Identification and targeting leukemia stem cells: the path to the cure for acute myeloid leukemia","volume":"6","author":"Zhou","year":"2014","journal-title":"World J Stem Cells"},{"key":"10.1016\/j.neo.2017.10.008_bb0120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2007-10-118331","article-title":"Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells","volume":"112","author":"Taussig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.neo.2017.10.008_bb0125","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/blood-2016-02-695312","article-title":"Evolution of acute myelogenous leukemia stem cell properties after treatment and progression","volume":"128","author":"Ho","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.neo.2017.10.008_bb0130","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1182\/blood-2012-10-464677","article-title":"AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model","volume":"121","author":"Wunderlich","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.neo.2017.10.008_bb0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3324\/haematol.2009.009811","article-title":"Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia","volume":"95","author":"Zhao","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.neo.2017.10.008_bb0140","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell\u2013associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.neo.2017.10.008_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neo.2017.10.008_bb0150","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/ijc.25806","article-title":"Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+\/CD38\u2212 cells and sensitizes them to antileukemia agents","volume":"128","author":"Ikezoe","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.neo.2017.10.008_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.neo.2017.10.008_bb0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-016-0292-z","article-title":"Immunoprofiling of leukemic stem cells CD34+\/CD38\u2212\/CD123+ delineate FLT3\/ITD-positive clones","volume":"9","author":"Al-Mawali","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.neo.2017.10.008_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev"},{"key":"10.1016\/j.neo.2017.10.008_bb0170","first-page":"4","article-title":"Emerging molecular and immune therapies in acute myeloid leukemia","volume":"13","author":"Boddu","year":"2017","journal-title":"Am J Hematol"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558617304190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558617304190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T18:28:34Z","timestamp":1535221714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558617304190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1476558617304190"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2017.10.008","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}